These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8782453)

  • 1. A pharmacologic rheostat for gene therapy.
    Wilson JM
    Nat Med; 1996 Sep; 2(9):977-8. PubMed ID: 8782453
    [No Abstract]   [Full Text] [Related]  

  • 2. A humanized system for pharmacologic control of gene expression.
    Rivera VM; Clackson T; Natesan S; Pollock R; Amara JF; Keenan T; Magari SR; Phillips T; Courage NL; Cerasoli F; Holt DA; Gilman M
    Nat Med; 1996 Sep; 2(9):1028-32. PubMed ID: 8782462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein matchmaker may lead new gene therapy to the altar.
    Balter M
    Science; 1996 Jul; 273(5272):183. PubMed ID: 8668994
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanism of action of rapamycin (Sirolimus, Rapamune).
    Molnar-Kimber KL
    Transplant Proc; 1996 Apr; 28(2):964-9. PubMed ID: 8623482
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of effects of sirolimus on cytokine dependent and cytokine independent proliferation.
    Molnar-Kimber KL; Rhoad A; Warner L; Chen H; Sehgal SN
    Inflamm Res; 1995 Aug; 44 Suppl 2():S189-90. PubMed ID: 8548391
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of rapamycin on hematopoiesis.
    Quesniaux VF; Wehrli S; Wioland C; Schuler W; Schreier MH
    Transplant Proc; 1994 Dec; 26(6):3135-40. PubMed ID: 7998093
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemical modification of rapamycin: the discovery of SDZ RAD.
    Sedrani R; Cottens S; Kallen J; Schuler W
    Transplant Proc; 1998 Aug; 30(5):2192-4. PubMed ID: 9723437
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclosporin A, FK506, and rapamycin: binding to immunophilins and biological action.
    Bierer BE
    Chem Immunol; 1994; 59():128-55. PubMed ID: 7524531
    [No Abstract]   [Full Text] [Related]  

  • 9. Dimeric ligands define a role for transcriptional activation domains in reinitiation.
    Ho SN; Biggar SR; Spencer DM; Schreiber SL; Crabtree GR
    Nature; 1996 Aug; 382(6594):822-6. PubMed ID: 8752278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 27-O-demethylrapamycin, an immunosuppressant compound produced by a new strain of Streptomyces hygroscopicus.
    Box SJ; Shelley PR; Tyler JW; Verrall MS; Warr SR; Badger AM; Levy MA; Banks RM
    J Antibiot (Tokyo); 1995 Nov; 48(11):1347-9. PubMed ID: 8557579
    [No Abstract]   [Full Text] [Related]  

  • 11. Rapamycin resistance in ataxia-telangiectasia.
    Beamish H; Williams R; Chen P; Khanna KK; Hobson K; Watters D; Shiloh Y; Lavin M
    Oncogene; 1996 Sep; 13(5):963-70. PubMed ID: 8806686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antascomicins A, B, C, D and E. Novel FKBP12 binding compounds from a Micromonospora strain.
    Fehr T; Sanglier JJ; Schuler W; Gschwind L; Ponelle M; Schilling W; Wioland C
    J Antibiot (Tokyo); 1996 Mar; 49(3):230-3. PubMed ID: 8626235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of inhibition of phosphoinositide 3-kinase enzyme activity by FKBP12/rapamycin.
    Hollis CM; Hutchinson R
    Biochem Soc Trans; 1996 Feb; 24(1):66S. PubMed ID: 8674742
    [No Abstract]   [Full Text] [Related]  

  • 14. Induction of CD5 on B and T cells is suppressed by cyclosporin A, FK-520 and rapamycin.
    Teutsch M; Higer M; Wang D; Wortis HW
    Int Immunol; 1995 Mar; 7(3):381-92. PubMed ID: 7540861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin.
    Carlson RP; Sehgal SN; Lewis AJ
    Clin Exp Rheumatol; 1993; 11 Suppl 8():S129. PubMed ID: 8324938
    [No Abstract]   [Full Text] [Related]  

  • 16. FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes.
    DeCenzo MT; Park ST; Jarrett BP; Aldape RA; Futer O; Murcko MA; Livingston DJ
    Protein Eng; 1996 Feb; 9(2):173-80. PubMed ID: 9005438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the mode of action of cyclosporine and FK 506.
    Hutchinson IV; Bagnall W; Bryce P; Pufong B; Geraghty P; Brogan I
    Transplant Proc; 1998 Jun; 30(4):959-60. PubMed ID: 9636388
    [No Abstract]   [Full Text] [Related]  

  • 18. A nonnatural transcriptional coactivator.
    Nyanguile O; Uesugi M; Austin DJ; Verdine GL
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13402-6. PubMed ID: 9391036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assignment of the human FKBP12-rapamycin-associated protein (FRAP) gene to chromosome 1p36 by fluorescence in situ hybridization.
    Moore PA; Rosen CA; Carter KC
    Genomics; 1996 Apr; 33(2):331-2. PubMed ID: 8660990
    [No Abstract]   [Full Text] [Related]  

  • 20. An FKBP-rapamycin-sensitive, cyclin-dependent kinase activity that correlates with the FKBP-rapamycin-induced G1 arrest point in MG-63 cells.
    Albers MW; Brown EJ; Tanaka A; Williams RT; Hall FL; Schreiber SL
    Ann N Y Acad Sci; 1993 Nov; 696():54-62. PubMed ID: 8109857
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.